mCRPC VL

Outcomes from The PROCEED Registry: Survival of African-American and Caucasian Men After Sipuleucel-T Immunotherapy - Oliver Sartor

Details
The large registry, PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data (PROCEED) (NCT01306890), evaluated sipuleucel-T immunotherapy for asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Oliver Sartor, the primary author joins Alicia Morgans to provide an update on the PROCEED registry aiming to understand outcomes for Afr...

Optimal Treatment Sequencing in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Evan Yu

Details
In an area where we have multiple options for treatment and we continue to have more data that helps to guide us, Evan Yu joins Alicia Morgans to speak about systemic treatment sequencing in the metastatic castration-resistant prostate cancer (mCRPC) setting and his approach to moving a patient through the different phases of their treatment. Biographies: Evan Yu, MD, Medical oncologist, treats pr...

The ORIOLE Trial Results Discussed: Outcomes of Observation vs SABR for Oligometastatic Prostate Cancer - Phuoc T. Tran

Details
The ORIOLE Phase 2 Randomized Clinical Trial set out to answer the question, "how effectively does stereotactic ablative radiotherapy prevent progression of disease compared with observation in men with recurrent hormone-sensitive prostate cancer with 1 to 3 metastases?" Dr Tran joins Alicia Morgans and discusses this phase 2 randomized clinical trial of 54 men, where the progression of disease at...

The Clinical Implications and Health-related Quality of Life Benefits: Reviewing the CARD Study Results in Men with mCRPC - Neal Shore

Details
Alicia Morgans and Neal Shore discuss the clinical implications of the CARD study, a phase 4 study demonstrating the first third-line treatment for metastatic castration-resistant prostate cancer (mCRPC), that prolonged overall survival with cabazitaxel as compared to treatment with a second AR targeted agent in men who had docetaxel and the alternative AR targeted agent in their prior treatment h...

CARD Study Demonstrates Cabazitaxel Improves Pain and Health-Related Quality of Life Analysis in Patients with mCRPC - Karim Fizazi

Details
In this discussion on the CARD trial with Alicia Morgans, Karim Fizazi discusses the study design, rationale, treatment strategy, and quality of life endpoints from the ASCO GU 2020 presentation: Pain Response and Health-Related Quality of Life Analysis in Patients with Metastatic Castration-Resistant Prostate Cancer from the CARD study. The objective of the QoL analysis was focused on three parti...

Optimal Steroid Use with Abiraterone - Gerhardt (Gert) Attard

Details
Gerhardt Attard joins Charles Ryan to discuss the optimal steroid and dose to be given with abiraterone for the management of castration-resistant prostate cancer (CRPC). The two review the risks and benefits of either the standard dose of 5mg prednisone BID compared to a lower steroid dose of 5mg daily. Dr. Attard also shares his perspective on using dexamethasone, which has also shown to have an...

RET Signaling in Neuroendocrine Prostate Cancer - Justin Drake

Details
Justin Drake, University of Minnesota, discusses the latest and ongoing research associated with the correlation between RET gene expression and neuroendocrine prostate cancer. The recent data shows enhanced RET gene expression in patients that have this AR negative neuroendocrine positive phenotype. Drake also highlighted his work in the development of noninvasive ways of detecting RET signaling...

Radiation Oncology Studies: Changing the Course of Disease for Men with Metastatic Prostate Cancer - Phuoc Tran

Details
Phuoc Tran, Johns Hopkins University, provides an overview of several ongoing clinical trials for prostate cancer. SALV-ENZA is a Phase II randomized placebo-controlled trial of salvage radiation, which then randomizes to either to placebo or the oral next-generation antiandrogen drug known as enzalutamide. Dr. Tran also reviews the ORIOLE and RAVENS clinical trials which examine metastasis-direct...

Bone Health Agents in Patients with Castrate-Resistant Prostate Cancer - Bertrand Tombal

Details
Neal Shore and Bertrand Tombal discuss the importance of bone health agents, particularly in patients receiving castrate-resistant prostate cancer agents. Highlights of their conversation include the use of antiresorptive therapy to reduce the risk of skeletal-related events in men with bone mCRPC and decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial. Bi...

Antibody-drug Conjugates for Metastatic Urothelial Carcinoma & 177Lu-PSMA-617 for Progressive mCRPC - Scott Tagawa

Details
Scott Tagawa joins Alicia Morgans at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) and discusses advances in bladder and prostate cancer. He highlights his recent work on antibody-drug conjugates (ADCs) specifically, sacituzumab govitecan in metastatic urothelial cancer and the and the initial results from TROPHY-U-01. Although immune checkpoint inhibitors now provide an...